Professor Di Wen, Research Fellow Yang Fan, Research Fellow Zhuang Guanglei, and other scholars from Renji Hospital, Shanghai Jiao Tong University School of Medicine, jointly published a landmark research achievement in Nature Biomedical Engineering (IF=26.6). The team independently developed a novel trispecific antibody, B7H3xCD3xPDL1, which innovatively integrates three core functions: tumor targeting, T cell activation, and immune microenvironment remodeling. Through a unique IFNγ-IL-15 positive feedback loop, the antibody successfully activates bystander T cells in the tumor microenvironment and reverses the immunosuppressive state, thereby providing an entirely new therapeutic approach for intractable solid tumors such as ovarian cancer and colorectal cancer. This groundbreaking achievement has garnered high recognition from the global academic community.